Compare Natera Inc. Common Stock (NTRA) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Oscar Health Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Oscar Health Inc trades at $34.01 (market cap $10.59B). The key difference: Natera Inc. Common Stock is far larger — about 5.4× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Oscar Health Inc for 15 Days on average.
| NTRA | OSCR | |
|---|---|---|
Market Cap | $57.03B | $10.59B |
Volume | 1,131,157 | 5,280,571 |
Sector | Health | Health |
52-Week High | $425.64 | $34.32 |
52-Week Low | $179.42 | $10.85 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | $6.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Oscar Health (OSCR) trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B projected for 2026, with profitability turning positive from a $443M loss to $551M net income. Recent earnings beats in Q1 and Q2 2026 exceeded expectations by significant margins, while analyst sentiment remains mixed with a $34.75 consensus target slightly above current levels.
OSCR presents a growth story with expanding market share in ACA plans and improved medical loss ratios, though profitability remains sensitive to medical cost trends. The stock faces near-term resistance at $35 with RSI suggesting potential overbought conditions. Key risks include execution on growth targets and healthcare cost pressures, while institutional interest remains strong with recent price target upgrades following positive guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
